SCHEMBL2934486

SCHEMBL2934486

CC(C)(C)OC(=O)n1c(OBOc2cc3ccccc3n2C(=O)OC(C)(C)C)cc2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 19/20 0.53
NR1H3 Q13133 3/20 0.50
CA12 O43570 1/20 0.49
CA9 Q16790 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12108168 0.90 NR1H2 (0.52) NR1H2NR1H3CA12CA9
SCHEMBL28370896 0.86 NR1H2 (0.55) NR1H2NR1H3CA12CA9
SCHEMBL2933363 0.83 NR1H2 (0.44) NR1H2NR1H3CA12CA9
SCHEMBL1564740 0.82 NR1H2 (0.52) NR1H2NR1H3CA12CA9
SCHEMBL5621589 0.80 KDM4E (0.37) NR1H2NR1H3CA12CA9
SCHEMBL30711377 0.80 NR1H2 (0.57) NR1H2NR1H3CA12CA9
SCHEMBL5713778 0.80 NR1H2 (0.57) NR1H2NR1H3CA12CA9
SCHEMBL17022654 0.80 NR1H2 (0.57) NR1H2NR1H3CA12CA9
SCHEMBL14765171 0.79 NR1H2 (0.39) NR1H2NR1H3CA12CA9
SCHEMBL12318752 0.79 NR1H2 (0.54) NR1H2NR1H3CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179046-A1 SEROTONIN 5-HT2B INHIBITORY COMPOUNDS ZOETIS SERVICES LLC 2025-06-05 US disclosed
CN-113631548-B Serotonin 5-HT2B inhibiting compounds 硕腾服务有限责任公司 2023-06-06 CN disclosed
CN-111225915-B Imidazopyridine compounds as PAD inhibitors 朱比兰特埃皮帕德有限公司 2023-03-07 CN disclosed
CN-113631548-A Serotonin 5-HT2B inhibiting compounds 硕腾服务有限责任公司 2021-11-09 CN disclosed
CN-111225915-A Imidazopyridine compounds as PAD inhibitors 朱比兰特埃皮帕德有限公司 2020-06-02 CN disclosed
EP-2753611-B1 SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME (US) 2018-04-11 EP disclosed
US-20150246902-A1 SUBSTITUED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2015-09-03 US disclosed
WO-2013034048-A1 SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2013-03-14 WO disclosed
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
WO-2007039146-A1 4-CARBOXY PYRAZOLE DERIVATIVES AS ANTI-VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2007-04-12 WO disclosed
EP-1421079-B1 THIOPHENYL COMPOUNDS AS MEDICAMENTS ASTRAZENECA AB (SE) 2007-02-07 EP disclosed
US-7098240-B2 Compounds ASTRAZENECA AB (SE) 2006-08-29 US disclosed
US-20040235821-A1 Novel compounds ASTRAZENECA AB (SE) 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 NR1H2 784/4885NR1H3 799/4885CA12 3948/4885
US-20250179046-A1 SEROTONIN 5-HT2B INHIBITORY COMPOUNDS HTR2B, HTR1B, HTR5A NR1H2 3935/4885NR1H3 4164/4885CA12 4380/4885
US-20150246902-A1 SUBSTITUED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES EIF5B, EIF2AK2, HCCS NR1H2 682/4885NR1H3 850/4885CA12 4311/4885
US-20040235821-A1 Novel compounds ABCG2, UGT1A1, SULT1E1 NR1H2 991/4885NR1H3 1183/4885CA12 2166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.